8-K: Curanex Pharmaceuticals Gets Nasdaq Delisting Warning Extension

Curanex Pharmaceuticals has received an additional 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement, now until November 2, 2026.

Summary

• Curanex Pharmaceuticals Inc. received a notification from Nasdaq on May 5, 2026, stating that its common stock's closing bid price has been below $1.00 for 30 consecutive business days.
• The company was initially given 180 days, until May 4, 2026, to regain compliance.
• Nasdaq has granted an additional 180-day compliance period, extending the deadline to November 2, 2026.
• This extension was granted because Curanex meets other Nasdaq Capital Market listing requirements, specifically the market value of publicly held shares.
• Curanex has informed Nasdaq of its intention to cure the deficiency, potentially through a reverse stock split.
• If the stock's closing bid price is at least $1.00 for 10 consecutive business days during this period, the matter will be closed.
• Failure to comply by November 2, 2026, will result in delisting, though the company may appeal to a Nasdaq Hearings Panel.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing, as while the company has secured an extension, the core issue of low stock price persists, and there's no guarantee of resolution.

Positives

• Curanex has been granted an additional 180-day period to regain compliance with Nasdaq's minimum bid price requirement.
• The company satisfies other Nasdaq Capital Market listing requirements, including the market value of publicly held shares.
• Nasdaq has acknowledged the company's intention to cure the deficiency.

Negatives

• The company's common stock closing bid price has been below the $1.00 minimum for 30 consecutive business days.
• The company has not yet regained compliance with the minimum bid price requirement.
• There is a risk of delisting from The Nasdaq Capital Market if compliance is not achieved by November 2, 2026.

Risks

• Potential delisting from The Nasdaq Capital Market if the closing bid price of the common stock does not reach at least $1.00 for 10 consecutive business days by November 2, 2026.
• There is no assurance that the company will be able to regain compliance with the Minimum Bid Price Requirement, even if other listing requirements are met.

Future Outlook

The company is monitoring its stock price and will consider options, including a reverse stock split, to regain compliance with the Nasdaq minimum bid price requirement by November 2, 2026. There is no guarantee of success.

Management Comments

• The Company is currently monitoring the closing bid price of its common stock and will consider available options, including a reverse stock split, if appropriate, to regain compliance with the Minimum Bid Price Requirement by November 2, 2026.
• There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement, even if it maintains compliance with other listing requirements of the Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that maintaining a minimum bid price is a common challenge for smaller-cap companies, and Nasdaq provides compliance periods and options like reverse stock splits to allow companies to rectify the situation before delisting.

Stakeholder Impact

• Shareholders: Potential for dilution if a reverse stock split is implemented, but also a chance to avoid delisting which would negatively impact liquidity and investor confidence.
• Creditors: No immediate impact indicated, but delisting could affect the company's financial stability and ability to service debt.
• Employees: Continued employment is contingent on the company's ability to remain listed and financially stable.

Next Steps

• Monitor the closing bid price of the common stock.
• Consider implementing a reverse stock split, if necessary.
• Regain compliance with the Minimum Bid Price Requirement by November 2, 2026.
• If compliance is not met, the company may appeal a delisting determination to a Nasdaq Hearings Panel.

Key Dates

Recommendation

The company has been granted an extension to address its low stock price, but the risk of delisting remains significant. While other listing requirements are met, the uncertainty surrounding the ability to regain compliance by November 2, 2026, warrants a cautious 'hold' recommendation until further clarity or positive action is demonstrated.

Keywords

Curanex Pharmaceuticals, Nasdaq, Delisting, Minimum Bid Price, Compliance, Reverse Stock Split, Form 8-K, SEC Filing